These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2893314)

  • 1. Intraventricular bethanechol infusion for Alzheimer's disease: results of double-blind and escalating-dose trials.
    Penn RD; Martin EM; Wilson RS; Fox JH; Savoy SM
    Neurology; 1988 Feb; 38(2):219-22. PubMed ID: 2893314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracerebroventricular bethanechol chloride infusion in Alzheimer's disease. Results of a collaborative double-blind study.
    Harbaugh RE; Reeder TM; Senter HJ; Knopman DS; Baskin DS; Pirozzolo F; Chui HC; Shetter AG; Bakay RA; Leblanc R
    J Neurosurg; 1989 Oct; 71(4):481-6. PubMed ID: 2571689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New intrathecal drugs in Alzheimer's disease and psychometric testing.
    Wilson RS; Martin EM
    Ann N Y Acad Sci; 1988; 531():180-6. PubMed ID: 2898228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease.
    Harbaugh RE; Roberts DW; Coombs DW; Saunders RL; Reeder TM
    Neurosurgery; 1984 Oct; 15(4):514-8. PubMed ID: 6149490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracerebroventricular bethanechol chloride administration in Alzheimer's disease.
    Harbaugh RE
    Ann N Y Acad Sci; 1988; 531():174-9. PubMed ID: 2898227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmitter-replacement therapy in Alzheimer's disease using intracerebroventricular infusions of receptor agonists.
    Gauthier S; Leblanc R; Robitaille Y; Quirion R; Carlsson G; Beaulieu M; Bouchard R; Dastoor D; Ervin F; Gauthier L
    Can J Neurol Sci; 1986 Nov; 13(4 Suppl):394-402. PubMed ID: 2878712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease. Using direct drug infusion to the central nervous system.
    Reeder TM; Hohmann M
    AORN J; 1986 Aug; 44(2):222, 224-30, 232. PubMed ID: 3530130
    [No Abstract]   [Full Text] [Related]  

  • 8. Intraventricular bethanechol in Alzheimer's disease: a continuing controversy.
    Whitehouse PJ
    Neurology; 1988 Feb; 38(2):307-8. PubMed ID: 2893315
    [No Abstract]   [Full Text] [Related]  

  • 9. Intracerebroventricular bethanechol for Alzheimer's disease. Variable dose-related responses.
    Read SL; Frazee J; Shapira J; Smith C; Cummings JL; Tomiyasu U
    Arch Neurol; 1990 Sep; 47(9):1025-30. PubMed ID: 1975738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracerebroventricular cholinergic drug administration in Alzheimer's disease: preliminary results of a double-blind study.
    Harbaugh RE
    J Neural Transm Suppl; 1987; 24():271-7. PubMed ID: 2890709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct cerebrospinal fluid infusion of bethanechol chloride in Alzheimer's disease: use of an implantable continuous infusion device.
    Reeder TM; Harbaugh RE
    J Neurosurg Nurs; 1985 Jun; 17(3):184-9. PubMed ID: 2861263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of parkinsonism by intraventricular bethanechol in a patient with Alzheimer's disease.
    Fox JH; Bennett DA; Goetz CG; Penn RD; Savoy S; Clasen R; Wilson RS
    Neurology; 1989 Sep; 39(9):1265. PubMed ID: 2570380
    [No Abstract]   [Full Text] [Related]  

  • 13. The necessity of human trials of putative therapies for Alzheimer's disease.
    Knopman D
    Neurobiol Aging; 1989; 10(5):633-4; discussion 648-50. PubMed ID: 2572987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery to the brain by central infusion: clinical application in patients with Alzheimer's disease.
    Harbaugh RE
    Int Clin Psychopharmacol; 1986 Jan; 1(1):77-83. PubMed ID: 2881962
    [No Abstract]   [Full Text] [Related]  

  • 15. Methodological considerations in cognitive disorders or: "the baby needs enough bath water".
    Read S
    Neurobiol Aging; 1989; 10(5):634-5; discussion 648-50. PubMed ID: 2572988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind controlled trial of bethanechol and antacid versus placebo and antacid in the treatment of erosive esophagitis.
    Saco LS; Orlando RC; Levinson SL; Bozymski EM; Jones JD; Frakes JT
    Gastroenterology; 1982 Jun; 82(6):1369-73. PubMed ID: 7040158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group.
    DeKosky ST; Harbaugh RE; Schmitt FA; Bakay RA; Chui HC; Knopman DS; Reeder TM; Shetter AG; Senter HJ; Markesbery WR
    Ann Neurol; 1992 Nov; 32(5):625-32. PubMed ID: 1360195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reflux esophagitis: effect of oral bethanechol on symptoms and endoscopic findings.
    Thanik KD; Chey WY; Shah AN; Gutierrez JG
    Ann Intern Med; 1980 Dec; 93(6):805-8. PubMed ID: 7004292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stable bimodal response to cholinomimetic drugs in Alzheimer's disease. Brain mapping correlates.
    Leuchter AF; Read SL; Shapira J; Walter DO; Smith C
    Neuropsychopharmacology; 1991 May; 4(3):165-73. PubMed ID: 1676588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.